Trial Profile
Longitudinal pilot study assessing tetrahydrocannabinol-cannabidiol (THC/CBD) oromucosal spray in patients with multiple sclerosis bladder dysfunction
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 29 Oct 2018
Price :
$35
*
At a glance
- Drugs Nabiximols (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 29 Oct 2018 New trial record
- 12 Oct 2018 Results of analysis of this preliminary data (n=14) evaluating effect of THC/CBD oromucosal spray on urodynamic parameters presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.